Key Points
- COO Ross Moat sold 75,608 Kiniksa shares for about $7.04 million, reducing his stake by 88% to 10,294 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Moat also sold 27,977 shares on November 2; reported insider sales across several executives and insiders totaled about 272,600 shares, worth roughly $25.4 million.
- Kiniksa beat quarterly earnings expectations, reporting EPS of $0.56 versus the $0.37 consensus and revenue of $285.97 million versus $260.66 million expected.
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider John Paolini sold 18,413 shares of the company's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $93.39, for a total transaction of $1,719,590.07. Following the sale, the insider directly owned 69,922 shares in the company, valued at $6,530,015.58. This trade represents a 20.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kiniksa Pharmaceuticals International Trading Up 2.7%
Shares of Kiniksa Pharmaceuticals International stock opened at $93.29 on Wednesday. The business has a 50-day moving average price of $79.67 and a two-hundred day moving average price of $60.56. Kiniksa Pharmaceuticals International, plc has a 1-year low of $37.02 and a 1-year high of $98.48. The company has a market cap of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.07.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals International
Institutional investors have recently made changes to their positions in the stock. Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company's stock worth $180,562,000 after purchasing an additional 421,347 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Kiniksa Pharmaceuticals International by 41.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company's stock valued at $64,182,000 after buying an additional 251,578 shares during the period. Dimensional Fund Advisors LP increased its position in Kiniksa Pharmaceuticals International by 18.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company's stock valued at $39,086,000 after buying an additional 128,417 shares in the last quarter. Spruce Street Capital LP increased its position in Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company's stock valued at $36,645,000 after buying an additional 326,081 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company's stock worth $35,436,000 after buying an additional 506,576 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.
Key Headlines Impacting Kiniksa Pharmaceuticals International
Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:
- Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing
Analysts Set New Price Targets
KNSA has been the subject of a number of research analyst reports. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a report on Wednesday, October 28th. Zacks Research cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 30th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Canaccord Genuity Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Finally, Citigroup lifted their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a research note on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $100.57.
Check Out Our Latest Stock Report on KNSA
Kiniksa Pharmaceuticals International Company Profile
(
Get Free Report)
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
